SHANGHAI, China, March 17 /Xinhua-PRNewswire/ -- WuXi PharmaTech is pleased to announce today that it has signed agreements with NeoTrident Technology and Elsevier MDL to significantly increase the user seats of CrossFire Beilstein and MDL Patent Chemistry Database platforms, effectively making WuXi PharmaTech the largest Beilstein industry customer in China. WuXi PharmaTech also has substantially increased the number of installed MDL ISIS/Base, ISIS/Draw and ISIS for Excel, software for better compound and database management.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
The CrossFire Beilstein database is the world’s largest compilation of chemical facts and the MDL Patent Chemistry Database indexes chemical reactions, substances and substance related information from organic chemistry and life sciences patent publications. These databases are indispensable in generating new leads, planning synthetic routes, determining bioactivity and physical properties.
Making Elsevier MDL chemistry databases widely accessible to chemists will greatly improve the overall drug discovery and development productivity and quality at WuXi PharmaTech. The installation of the two databases also exemplifies WuXi PharmaTech’s commitment to IP protection. Unofficial and unregistered chemistry software and databases use remains prevalent and unchecked in China. As the staunchest IP protection champion, WuXi PharmaTech is well recognized by its collaboration partners for setting high IP standards in China.
''As China’s world-class drug discovery and development services company, WuXi PharmaTech has been the staunchest IP protection champion in China from its inception, therefore we are very pleased to work with it.’' Mr. Lingxiao Cao, General Manager of NeoTrident Technology said.
Dr. Ge Li, Chairman and CEO of WuXi PharmaTech said, “The agreements with NeoTrident and Elsevier MDL give us state-of-the-art chemistry databases. Having scientific and technical information conveniently available to our scientists is essential in providing high quality research work to our clients. Engaging content provider like Elsevier MDL shows our unwavering commitment to quality, integrity and IP protection.’'
About WuXi PharmaTech
Founded in 2001, the Shanghai-based WuXi PharmaTech Co., Ltd., is the leader in the pharmaceutical R&D services industry in China. WuXi PharmaTech assists global pharmaceutical and biopharmaceutical companies in shortening the cycle and lowering the cost of drug research and development, and helps clients fully leverage the lower cost R&D capacity in China.
As an integrated drug R&D outsourcing service company, WuXi PharmaTech provides discovery and development services to our partners from lead identification to pre-clinical through our state-of-the-art facilities. The company has a broad service spectrum ranging from lead generation and optimization, in vivo and in vitro ADMET profiling, bioanalytical services, to chemistry process development and large scale manufacturing. There are over 750 scientific staff members and its management team consists of veterans from U.S., India and Japan pharmaceutical industry. WuXi PharmaTech has a 360,000 sq. ft. state-of-the-art research center in WaiGaoQiao Free Trade Zone and a 250,000 sq. ft. and ISO 9001:2000 certified GMP plant in Jinshan Chemical Industry Development Zone, Shanghai. The company’s customers include 19 of the top 20 pharmaceutical companies and 8 of the top 10 biopharmaceutical companies in the world.
About NeoTrident Technology Ltd.
NeoTrident (http://www.neotrident.com) is the leading Informatics solutions company in the fields of biological and material sciences in China. NeoTrident systematically provides molecular modeling technological products, comprehensive chemical information and workflow managing platforms as well as professional chemical information and intelligence services, respectively. With the business headquarter firmly rooted in Beijing, NeoTrident branches its technology support and research center in Shanghai, and running center in Hong Kong. NeoTrident has over 300 customers in China, among which include the largest pharmaceutical companies in China, the best new drug research CROs (contract research organization), the most famous petroleum giants and all the main universities and research institutions.
About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit http://www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit http://www.elsevier.com.
For more information, please contact: David Yin WuXi PharmaTech, Public Relations Tel: +86-21-5046-4003 Email: yin_xiaojun@pharmatechs.com
WuXi PharmaTech Co., Ltd.,
CONTACT: David Yin of WuXi PharmaTech, Public Relations, +86-21-5046- 4003or yin_xiaojun@pharmatechs.com
